HK Stocks in Focus | Perma Medical-B (09996) Surges Over 6% in Morning Trading as Neurointerventional Products Show Strong Growth; Chairman Plans to Continue Increasing Shareholding

LootboxPhobia · 2026-03-26T04:28:03+00:00

Perma Health announces annual results with year-over-year revenue growth of 15.82% and narrowed shareholder losses. TAVR and neurointerventional product sales show significant growth. The company CEO plans to continue increasing shareholdings, demonstrating confidence in the company's future development.

LootboxPhobia

2026-03-26 04:28:03

Abstract generation in progress

Smart Ticker Finance APP reports that Peijia Medical-B (09996) rose over 6% in early trading. As of the time of writing, it increased by 6.69%, trading at HKD 6.06, with a turnover of HKD 11.85 million.

On the news front, Peijia Medical released its annual results, showing the group achieved revenue of RMB 713 million, a year-on-year increase of 15.82%; shareholder net loss narrowed by 10.28% year-on-year. The announcement indicated that during the period, sales revenue of TAVR-related products increased by 11.6% year-on-year to RMB 290 million; sales revenue of neurointerventional products increased by 18.9% year-on-year to RMB 423 million; profit from this segment grew by 86.6% to RMB 97.2 million.

The company also stated that Executive Director, CEO, and Chairman Dr. Zhang Y, through his controlled companies, plans to continue purchasing shares on the open market starting from March 26. The total cost of these share purchases is not expected to exceed HKD 15 million. Depending on applicable laws and regulations, there is also the possibility of further increasing his stake in the company at an appropriate time.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.